Scott F. Huntington, MD, MPH

Articles by Scott F. Huntington, MD, MPH

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia

ByJalpa A. Doshi, PhD,Pengxiang Li, PhD,Hairong Huo, PhD, MS,Amy R. Pettit, PhD,Rishab Kumar,Brendan M. Weiss, MD,Scott F. Huntington, MD, MPH

March 18th 2016

A Medicare claims analysis of patients newly diagnosed with chronic myeloid leukemia revealed that high cost sharing was associated with reduced and/or delayed tyrosine kinase inhibitor initiation under Part D.

Latest Updated Articles

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia
Published: March 18th 2016 | Updated:

Scott F. Huntington, MD, MPH

Articles by Scott F. Huntington, MD, MPH

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia

Latest Updated Articles

Trending on AJMC

FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

New Insight on Biologic Initiation Patterns for Treating Severe Asthma

Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS

Predicting Patient Response in the Move Toward Precision Medicine in Myasthenia Gravis

Planetary Health Highlights Global Links Between Climate, Respiratory Well-Being